What is the recommended amoxicillin‑clavulanic acid (Amoxyclav) dose for adults and children, and how should it be adjusted for renal impairment or penicillin allergy?

Amoxicillin-Clavulanate (Amoxyclav) Dosing Guidelines

For adults with normal renal function, prescribe amoxicillin-clavulanate 875 mg/125 mg twice daily for most infections, escalating to 2000 mg/125 mg twice daily when resistance risk factors are present; for children, use high-dose 90 mg/kg/day amoxicillin + 6.4 mg/kg/day clavulanate divided every 12 hours as first-line therapy. 1

Adult Dosing Regimens

Standard-Dose (Uncomplicated Infections)

• 875 mg/125 mg twice daily for 5–7 days is the preferred regimen for respiratory tract infections in patients without resistance risk factors, achieving 83–88% predicted clinical efficacy. 1
• 625 mg (500 mg/125 mg) three times daily is an alternative for respiratory infections and represents the standard dosing in many European guidelines. 2, 3
• Duration is typically 7–10 days for most respiratory infections, though 5–7 days is sufficient for uncomplicated acute bacterial rhinosinusitis. 1, 3

High-Dose (Resistance Risk Factors Present)

• 2000 mg/125 mg twice daily for 7 days when any of the following risk factors exist: 1, 3

  • Antibiotic use within the past 30 days
  • Age > 65 years
  • Daycare exposure or close contact with children in daycare
  • Moderate-to-severe infection severity
  • Frontal or sphenoidal sinusitis
  • Comorbidities (diabetes, chronic cardiac/pulmonary/hepatic/renal disease)
  • Immunocompromised status
  • Smoking or exposure to smokers
  • Community prevalence of penicillin-resistant S. pneumoniae > 10%
  • Prior treatment failure with standard antibiotics
  • Healthcare environment exposure

• High-dose therapy achieves 90–92% predicted clinical efficacy against penicillin-resistant S. pneumoniae with MICs up to 4–8 mg/L, compared to 83–88% for standard dosing. 1, 3

Intravenous Dosing (Severe Infections)

• 1.2 g (1000 mg amoxicillin/200 mg clavulanate) every 6–8 hours IV for moderate-to-severe infections in adults. 1
• Switch to oral formulation as soon as clinically appropriate, typically within 48–72 hours if improving. 2, 1

Pediatric Dosing Regimens

High-Dose (Preferred First-Line)

• 90 mg/kg/day amoxicillin + 6.4 mg/kg/day clavulanate divided every 12 hours (maximum 4000 mg/day amoxicillin) for 10 days. 1, 4
• This 14:1 amoxicillin-to-clavulanate ratio reduces diarrhea incidence while maintaining efficacy against β-lactamase-producing organisms. 4
• Maximum single dose is 2000 mg amoxicillin per administration regardless of weight. 4

Indications for High-Dose in Children

Use 90 mg/kg/day when any of these factors are present: 4

• Age < 2 years
• Daycare attendance
• Antibiotic use within the past 30 days
• Incomplete Hib vaccination (< 3 doses)
• Community prevalence of penicillin-resistant S. pneumoniae > 10%
• Moderate-to-severe illness at presentation
• Concurrent purulent acute otitis media
• Prior treatment failure with amoxicillin alone

Standard-Dose (Limited Use)

• 45 mg/kg/day amoxicillin + 6.4 mg/kg/day clavulanate divided every 12 hours for uncomplicated infections in children without risk factors. 1, 4

Age-Based Dosing (Mild Infections Only)

For children with mild infections and no risk factors: 2, 4

• Birth–1 year: 0.266 mL/kg of 125/31 mg/mL suspension three times daily
• 1–6 years: 5 mL of 125/31 mg/mL suspension three times daily
• 7–12 years: 5 mL of 250/62 mg/mL suspension three times daily
• 12–18 years: 1 tablet (250 mg/125 mg) three times daily

Critical caveat: These age-based doses deliver substantially lower amoxicillin exposure than the high-dose regimen and should be reserved only for mild infections without any resistance risk factors. 4

Intravenous Dosing (Severe Pediatric Infections)

• 30 mg/kg every 8 hours IV for moderate infections across all pediatric ages. 2, 1, 4
• For severe infections or undrained abscesses, increase to 200 mg/kg/day divided every 6 hours IV (maximum 4 g/day). 1, 4
• Doses may be doubled in severe infections for both oral and IV formulations. 2, 4

Renal Impairment Adjustments

Adults

• CrCl 10–30 mL/min: Reduce dosing frequency to every 12 hours OR decrease dose by 50%. 1
• CrCl < 10 mL/min: Reduce dosing frequency to every 24 hours OR decrease dose by 75%. 1
• Hemodialysis: Administer supplemental dose after each dialysis session. 1, 5

Important pharmacokinetic consideration: Amoxicillin clearance decreases more dramatically than clavulanate clearance in renal impairment, resulting in a progressively higher amoxicillin-to-clavulanate ratio as GFR declines. 5 The ratio increases from 4.9:1 at GFR 75 mL/min to 14.7:1 in hemodialysis patients. 5

Pediatrics

• Apply proportional dose reductions based on estimated creatinine clearance, mirroring adult adjustments. 1
• Specific pediatric renal dosing guidelines are limited; clinical judgment is required. 1

Augmented Renal Clearance (Critically Ill)

• In critically ill children with augmented renal clearance, 25 mg/kg every 4 hours is required to achieve therapeutic targets for both amoxicillin and clavulanate. 6
• A 1-hour infusion is preferable to bolus dosing in patients with augmented renal function. 6
• Current standard dosing results in subtherapeutic concentrations in early sepsis due to augmented clearance, risking clinical failure. 6

Penicillin Allergy Alternatives

Non-Type I (Non-Anaphylactic) Allergy

• Clindamycin + third-generation oral cephalosporin (e.g., cefpodoxime, cefdinir) for respiratory infections. 4, 3
• Second- or third-generation cephalosporins with renal dose adjustment for patients with mild allergy history. 3

Type I (Anaphylactic) Allergy

• Respiratory fluoroquinolones: Levofloxacin or moxifloxacin for adults. 2, 3
• Clarithromycin for children: 2, 4
  • < 1 year: 7.5 mg/kg twice daily
  • 1–2 years: 62.5 mg twice daily
  • 3–6 years: 125 mg twice daily
  • 7–9 years: 187.5 mg twice daily
  • ≥ 10 years: 250 mg twice daily
• Vancomycin 30 mg/kg/day IV in 2 doses for serious infections when desensitization cannot be performed. 2

Clinical Reassessment Protocol

Adults

• At 48–72 hours: Evaluate clinical response; lack of improvement warrants diagnostic reconsideration or antibiotic escalation. 1, 3
• At 3–5 days: If no improvement, switch to high-dose amoxicillin-clavulanate (if not already prescribed) or a respiratory fluoroquinolone. 3
• At 7 days: Persistent or worsening symptoms require imaging, cultures, and possible ENT referral. 3

Children

• At 72 hours: Lack of improvement or clinical worsening mandates escalation to high-dose amoxicillin-clavulanate or alternative therapy. 4, 3
• Continue treatment for an additional 7 days after symptom resolution to ensure complete eradication. 3

Common Prescribing Pitfalls

Underdosing in High-Risk Patients

• Using standard 875 mg/125 mg dosing in adults with resistance risk factors results in 20–25% treatment failure rates. 3
• Using age-based dosing instead of weight-based high-dose (90 mg/kg/day) in children with risk factors leads to subtherapeutic exposure and promotes resistance. 4

Suspension Concentration Errors

• Always verify whether the suspension is 125/31 mg/mL or 250/62 mg/mL before calculating volume to avoid dosing errors. 4

Inadequate Treatment Duration

• Courses shorter than 5 days in adults or 10 days in children increase relapse risk and promote antimicrobial resistance. 4, 3

Weight-Based Dosing Threshold

• For patients weighing ≥ 40 kg, use adult dosing rather than pediatric weight-based calculations to avoid dosing errors. 3

Adverse Effects

• Gastrointestinal disturbances (diarrhea, nausea, vomiting) occur in 15–40% of adults and ~25% of children, but rarely require discontinuation. 1, 3
• The 14:1 amoxicillin-to-clavulanate ratio in high-dose pediatric formulations reduces diarrhea incidence compared to other preparations. 4, 7
• Diarrhea is generally less frequent with twice-daily than three-times-daily dosing. 7

Special Clinical Situations

Critically Ill Patients on Renal Replacement Therapy

• RRT adds 48% to total drug clearance even in patients with normal native renal function. 8
• Consider 2.2 g every 6–8 hours with early therapeutic drug monitoring in critically ill patients receiving RRT. 8
• Target free antibiotic concentration above the MIC for > 40% of the dosing interval (fT>MIC > 40%). 8

Outpatient Parenteral Therapy

• Ceftriaxone 2 g IV/IM once daily is particularly convenient for outpatient therapy when oral medication cannot be tolerated. 2, 3

Abscess Management

• Primary treatment for fluctuant abscesses is incision and drainage; antibiotics alone are insufficient. 4

2, 1, 4, 3, 6, 5, 7, 9, 8